Table 3.
Differences between TIO/OLO 5/5 μg and PLA, TIO 5 µg monotherapy, and OLO 5 µg monotherapy for two patient-centred outcomes with response rates and numbers needed to treat.
| Study | TDI | TDI responders (%) | NNT (95% CI) | SGRQ | SGRQ responders (%) | NNT (95% CI) |
|---|---|---|---|---|---|---|
| TIO/OLO 5/5 µg versus PLA | ||||||
| Singh 1+211 | 2.1 and 1.2 | 53.9 versus 26.2 | 4 (3.1–4.2) | −4.89 and −4.59 | 53.1 versus 31.2 and 51.8 versus 32.6 |
5 (3.8–5.7) and 6 (4.2–6.6) |
| TIO/OLO 5/5 µg versus TIO 5 µg | ||||||
| Singh 1+211 | 0.6 and 0.6 | 53.9 versus 41.0 | 8 (5.8–11.7) | −2.49 and −1.72 | 53.1 versus 41.7 and 51.8 versus 41.1 |
9 (6.3–14.2) and 10 (6.6–15.7) |
| Buhl 1+212 | 0.4 | 54.9 versus 50.6 (NS) | 24 (NS) | −1.23 | 57.5 versus 48.7 | 12 (7.6–22.5) |
| TIO/OLO 5/5 µg versus OLO 5 µg | ||||||
| Buhl 1+212 | 0.4 | 54.9 versus 48.2 | 15 (9.0–42.9) | −1.69 | 57.5 versus 44.8 | 8 (5.9–12.0) |
CI, confidence interval; HR-QoL, health-related quality of life; NNT, number needed to treat; NS, nonsignificant; OLO, olodaterol; PLA, placebo; SGRQ, St. George’s respiratory questionnaire score; TDI, Transitional Dyspnea Index; TIO, tiotropium; TIO/OLO, tiotropium/olodaterol fixed-dose combination.